Skip to main content
Premium Trial:

Request an Annual Quote

US Appeals Court Upholds Invalidation of Columbia University Sequencing Chemistry Patents

NEW YORK – A US appeals court has upheld the invalidation of five patents covering next-generation sequencing chemistry held by Columbia University.

In an opinion released Monday, the US Court of Appeals for the Federal Circuit affirmed the US Patent and Trademark Office's Patent Trial and Appeals Board (PTAB) 2019 decision to invalidate US Patent Nos. 9,718,852; 9,719,139; 9,708,358; 9,725,480; and 9,868,985, all covering nucleotide analogs and their use in sequencing-by-synthesis. The invalidations were the result of several inter partes review (IPR) proceedings initiated by Illumina from 2017 to 2018.

The PTAB found that the patents would have been obvious given certain combinations of prior art. Columbia University appealed, challenging the determination that a person of ordinary skill in the art would have been motivated to pursue the claimed inventions or would have had a reasonable expectation of success.

The decision is a blow to a 2017 lawsuit filed by Columbia against Illumina, alleging infringement of the '358 patent.

Columbia University declined to comment; through an attorney, Illumina declined to comment.

The two parties have been embroiled in litigation over NGS technology for the better part of a decade. Columbia first sued Illumina in 2012, alleging infringement of four patents related to NGS chemistry, none of which were involved in the recent appeal. Illumina countersued and also sued Qiagen, which had licensed patents from Columbia.

Last year, Illumina initiated IPR proceedings over five more patents held by Columbia University, US Patent Nos. 10,407,458; 10,407,459; 10,457,984; 10,435,742; and 10,428,380 — all titled "Massive parallel method for decoding DNA and RNA." Over the last two months, the PTAB has instituted IPR for all five patents.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.